GlassScriptPhysician profile
Promila Dhanuka
NPI 1225094469
$9,532.00
in general payments reported to CMS, 2019-2025
50 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,592 · 2020: $928 · 2021: $1,448 · 2022: $1,849 · 2023: $1,943 · 2024: $802 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,501 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,501.49 |
| Education | $213.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $918.06 | 2019-2025 | |
| Daiichi Sankyo INC. | $665.81 | 2019-2025 | Injectafer, Enhertu |
| Janssen Biotech, INC. | $645.55 | 2019-2025 | Erleada, Akeega, Imbruvica |
| Novartis Pharmaceuticals Corporation | $594.91 | 2019-2025 | |
| Seagen INC. | $590.09 | 2019-2023 | Tukysa |
| Incyte Corporation | $521.16 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Eisai INC. | $516.01 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $412.33 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $382.61 | 2019-2025 | Enhertu |
| Astellas Pharma US INC | $376.70 | 2019-2025 | Xtandi, Padcev |
| Intuitive Surgical, INC. | $367.09 | 2020-2022 | |
| Amgen INC. | $303.13 | 2019-2023 | Nplate |
| Celgene Corporation | $288.31 | 2019-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $274.48 | 2019-2023 | Keytruda, Lynparza |
| Abbvie INC. | $263.24 | 2019-2025 | Venclexta |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $246.64 | 2019-2024 | Tecentriq, Ocrevus |
| Kite Pharma, INC. | $207.84 | 2020-2023 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $191.34 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Coherus Oncology, INC. | $141.58 | 2022 | |
| Organon LLC | $134.54 | 2021-2025 | Ontruzant |
| Rigel Pharmaceuticals, INC. | $130.68 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genzyme Corporation | $113.63 | 2019-2023 | |
| Tersera Therapeutics LLC | $111.34 | 2021-2025 | Quzyttir, Zoladex |
| Array Biopharma INC | $98.77 | 2020-2023 | Braftovi, Mektovi, Xalkori |
| Lilly USA, LLC | $98.28 | 2022-2023 | Jaypirca, Verzenio |
| Regeneron Healthcare Solutions, INC. | $93.40 | 2021-2024 | Libtayo |
| Gilead Sciences, INC. | $82.05 | 2019-2023 | |
| Servier Pharmaceuticals LLC | $67.41 | 2022-2023 | |
| Taiho Oncology, INC. | $61.72 | 2019-2023 | |
| Sobi, INC | $58.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.88 | 2019 | |
| Emd Serono, INC. | $54.40 | 2021-2022 | |
| Pharmaessentia USA Corporation | $46.94 | 2023-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $43.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $42.41 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $39.11 | 2019-2023 | Imbruvica |
| Geron Corporation | $33.28 | 2025 | Rytelo |
| Beigene USA, INC. | $28.49 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.19 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.31 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.26 | 2022 | |
| Secura Bio, INC. | $20.08 | 2020 | |
| Blueprint Medicines Corporation | $20.04 | 2025 | Ayvakit |
| Kyowa Kirin, INC. | $19.89 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.03 | 2019 | |
| Shire North American Group INC | $17.89 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.81 | 2023 | Givlaari |
| Morphosys, US INC. | $15.22 | 2023 | Monjuvi |
| Karyopharm Therapeutics INC. | $14.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Promila Dhanuka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.